Lv42
540 积分 2023-05-12 加入
CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
9天前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
10天前
已完结
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
11天前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
14天前
已完结
How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?
17天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
17天前
已完结
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
17天前
已完结
Efficacy and Safety of FcRn Inhibitors in Patients with Myasthenia Gravis: An Updated Systematic Review and Meta‑Analysis
23天前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
23天前
已完结
AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial
30天前
已完结
皖公网安备34019202002308
